Marloes Schaddelee

657 citations

21 papers · 517 indexed · h-index 12

Co-authors: Marcel van Gelderen John Meijer Walter Krauwinkel Selina Moy Donna Kowalski Jan van Dijk Albertus G. de Boer Adriaan P. IJzerman
Topics: Urinary Bladder and Prostate Research (7 papers)Erythropoietin and Anemia Treatment (4 papers)Pharmacological Effects and Toxicity Studies (4 papers)
Cited by: Urology Physiology Rheumatology
Journals: Journal of Pharmacology and Experimental Therapeutics European Journal of Pharmacology Clinical Pharmacology & Therapeutics
Partner nations: Netherlands United Kingdom Japan

In The Last Decade

Marloes Schaddelee

20 papers receiving 502 citations

Peers

Countries citing papers authored by Marloes Schaddelee

Since Specialization

Citations

This map shows the geographic impact of Marloes Schaddelee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marloes Schaddelee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marloes Schaddelee more than expected).

Fields of papers citing papers by Marloes Schaddelee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marloes Schaddelee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marloes Schaddelee. The network helps show where Marloes Schaddelee may publish in the future.

Co-authorship network of co-authors of Marloes Schaddelee

This figure shows the co-authorship network connecting the top 25 collaborators of Marloes Schaddelee. A scholar is included among the top collaborators of Marloes Schaddelee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marloes Schaddelee. Marloes Schaddelee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of PD-(L)1 inhibition in the treatment of endometrial cancer across molecular classes: a systematic review and meta-analysis 2025 ·International Journal of Gynecological Cancer ·(unknown),Marloes Schaddelee,Carien L. Creutzberg,Judith R. Kroep,Nanda Horeweg	0
2	Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals 2021 ·Clinical Therapeutics ·(unknown),(unknown),(unknown),(unknown),Jan van Dijk,Georg Golor,Marloes Schaddelee	11
3	Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects 2018 ·European Journal of Drug Metabolism and Pharmacokinetics ·(unknown),(unknown),Jan van Dijk,(unknown),Rachid El Galta,Georg Golor,Marloes Schaddelee	18
4	The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction Study 2016 ·Clinical Therapeutics ·(unknown),(unknown),(unknown),Axel Krebs‐Brown,(unknown),Georg Golor,Marloes Schaddelee	19
5	Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor 2016 ·Clinical Drug Investigation ·(unknown),(unknown),(unknown),(unknown),Axel Krebs‐Brown,Lyudmila Mateva,(unknown),Marloes Schaddelee	35
6	A quantitative benefit–risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder 2015 ·Clinical Pharmacology & Therapeutics ·(unknown),Donald Newgreen,Marloes Schaddelee,Caroline A. Dorrepaal,Reynaldo Martina,Arwin Ridder,(unknown)	7
7	D optimal designs for three Poisson dose–response models 2013 ·Journal of Pharmacokinetics and Pharmacodynamics ·Alan Maloney,Ulrika S. H. Simonsson,Marloes Schaddelee	5
8	The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol 2013 ·European Journal of Drug Metabolism and Pharmacokinetics ·Walter Krauwinkel,James Dickinson,Marloes Schaddelee,John Meijer,Reiner Tretter,(unknown),(unknown),Marcel van Gelderen	35
9	Absorption, Metabolism and Excretion of [14C]Mirabegron (YM178), a Potent and Selective β3-Adrenoceptor Agonist, after Oral Administration to Healthy Male Volunteers 2012 ·Drug Metabolism and Disposition ·(unknown),Jan Jaap van Lier,Katsuhiro Suzuki,Masanori Nagata,John Meijer,Walter Krauwinkel,Marloes Schaddelee,Mitsuhiro Sekiguchi,Aiji Miyashita,Takafumi Iwatsubo,Marcel van Gelderen,Takashi Usui	46
10	Effect of Renal or Hepatic Impairment on the Pharmacokinetics of Mirabegron 2012 ·Clinical Drug Investigation ·James Dickinson,(unknown),Taiji Sawamoto,Walter Krauwinkel,Marloes Schaddelee,James J. Keirns,(unknown),Selina Moy,John Meijer,Donna Kowalski,Richard E. Morton,Kenneth C. Lasseter,Dennis Riff,Viera Kupčová,Marcel van Gelderen	24
11	Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study 2012 ·Clinical Pharmacology & Therapeutics ·Marek Malík,E. Marcel van Gelderen,(unknown),Donna Kowalski,Mark Yen,Ronald Goldwater,Salim Mujais,Marloes Schaddelee,(unknown),Atsunori Kaibara,Selina Moy,James J. Keirns	112
12	Single dose pharmacokinetics and absolute bioavailability of mirabegron, a ?3-adrenoceptor agonist for treatment of overactive bladder 2012 ·International Journal of Clinical Pharmacology and Therapeutics ·(unknown),Jennifer Lee,Marloes Schaddelee,Wenhui Zhang,(unknown),John Meijer,Sjoerd van Marle,Nicole Grunenberg,Donna Kowalski,Ted Drogendijk,Selina Moy,(unknown),Marcel van Gelderen,Hiroshi Matsushima,Taiji Sawamoto	42
13	Pharmacokinetic Properties of Mirabegron, a β3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women 2012 ·Clinical Therapeutics ·Walter Krauwinkel,Jan van Dijk,Marloes Schaddelee,(unknown),John Meijer,(unknown),Sjoerd van Marle,(unknown),Marcel van Gelderen	71
14	An example of optimal phase II design for exposure response modelling 2010 ·Journal of Pharmacokinetics and Pharmacodynamics ·Alan Maloney,Marloes Schaddelee,Jan Freijer,Walter Krauwinkel,Marcel van Gelderen,Philippe Jacqmin,Ulrika S. H. Simonsson	3
15	Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain 2005 ·European Journal of Pharmacology ·Marloes Schaddelee,S D Collins,Joost DeJongh,Albertus G. de Boer,Adriaan P. IJzerman,Meindert Danhof	11
16	Population Pharmacokinetic Modeling of Blood-Brain Barrier Transport of Synthetic Adenosine A1 Receptor Agonists 2004 ·Journal of Pharmacology and Experimental Therapeutics ·Marloes Schaddelee,(unknown),Joost DeJongh,Cindy G. J. Cleypool,Adriaan P. IJzerman,Albertus G. de Boer,Meindert Danhof	4
17	Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents 2004 ·European Journal of Pharmaceutical Sciences ·Marloes Schaddelee,Kevin D. Read,(unknown),Adriaan P. IJzerman,Meindert Danhof,Albertus G. de Boer	20
18	Population pharmacokinetic–pharmacodynamic modelling of the anti-hyperalgesic effect of 5′deoxy-N6-cylopentyladenosine in the mononeuropathic rat 2004 ·European Journal of Pharmacology ·Marloes Schaddelee,Joost DeJongh,S D Collins,Albertus G. de Boer,Adriaan P. IJzerman,Meindert Danhof	4
19	Blood–brain barrier transport of synthetic adenosine A1 receptor agonists in vitro: structure transport relationships 2003 ·European Journal of Pharmaceutical Sciences ·Marloes Schaddelee,(unknown),(unknown),Anne Hersey,Adriaan P. IJzerman,Meindert Danhof,Albertus G. de Boer	14
20	Functional role of adenosine receptor subtypes in the regulation of blood–brain barrier permeability: possible implications for the design of synthetic adenosine derivatives 2003 ·European Journal of Pharmaceutical Sciences ·Marloes Schaddelee,(unknown),Erica W. van Tilburg,Tony Pateman,Adriaan P. IJzerman,Meindert Danhof,Albertus G. de Boer	29

About Marloes Schaddelee

Marloes Schaddelee is a scholar working on Urology, Physiology and Hematology, having authored 21 papers that have together received 517 indexed citations. Recurring topics across this work include Urinary Bladder and Prostate Research (7 papers), Erythropoietin and Anemia Treatment (4 papers) and Pharmacological Effects and Toxicity Studies (4 papers). The work is most often cited by research in Urology (216 citations), Physiology (45 citations) and Rheumatology (97 citations). Marloes Schaddelee has collaborated with scholars based in Netherlands, United Kingdom and Japan. Frequent co-authors include Marcel van Gelderen, John Meijer, Walter Krauwinkel, Selina Moy, Donna Kowalski, Jan van Dijk, Albertus G. de Boer, Adriaan P. IJzerman, Meindert Danhof and James J. Keirns. Their work appears in journals such as Journal of Pharmacology and Experimental Therapeutics, European Journal of Pharmacology and Clinical Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact